{"href":"https://api.simplecast.com/oembed?url=https%3A%2F%2Fskinandjointspodcast.simplecast.com%2Fepisodes%2Faad2026ltejakpart2-BaGDoLDj","width":444,"version":"1.0","type":"rich","title":"Age, Risk, and the JAK Factor: A 6-Year Safety Deep Dive from AAD 2026 ","thumbnail_width":300,"thumbnail_url":"https://image.simplecastcdn.com/images/017450d4-6458-4a10-9297-ca289770dc2d/324ddac1-dd83-4637-8020-459dda631a29/assaad.jpg","thumbnail_height":300,"provider_url":"https://simplecast.com","provider_name":"Simplecast","html":"","height":200,"description":"🎙️Age, Risk, and the JAK Factor: A 6-Year Safety Deep Dive- Part 2 \n\nGuests: Dr. Marissa Joseph and Dr. Fiona Lovegrove \nLocation: 📍 AAD 2026\n\nWe’re back with Part 2 of our atopic dermatitis double-header with Dr. Marissa Joseph and Dr. Fiona Lovegrove from AAD 2026 in Denver—and this time, we’re getting into the data that always enters the chat when JAK inhibitors in Atopic Dermatitis are mentioned: long-term safety.\n \nOur expert faculty unpack fresh 6-year safety data on upadacitinib in moderate-to-severe atopic dermatitis—looking beyond efficacy and into the real-world clinical questions dermatologists face every day:\n\n🧩 Who is the right patient?\n⚖️ How do we balance real world risk vs benefit?\n👵 Does anything change when a patient is over 65? Or is it about how risk is really framed?\n💉 Where does zoster vaccination fit into the treatment conversation?\n📊 And how do we contextualize MACE, VTE, malignancy, infections, and herpes zoster without turning nuance into noise?\n\nBecause let’s be honest: when it comes to JAK inhibitors, the safety conversation doesn’t just knock politely—it pulls up a chair. 🪑\n\nThis episode dives into how long-term data can help clinicians move beyond blanket “yes/no” thinking and toward more individualized decision-making: age, comorbidity stacking, dose, baseline risk, quality of life, disease severity, and patient preference all matter.\n\nThe big takeaway? Decisions in the gray zone—and that’s exactly where expert interpretation matters most.\n\n🎯 Learning Objectives:\nBy the end of this episode, listeners will be able to:\n1.\tDiscuss the clinical relevance of long-term safety data for upadacitinib in moderate-to-severe atopic dermatitis.\n2.\tIdentify key safety considerations, including herpes zoster, serious infections, MACE, VTE, and malignancy.\n3.\tDescribe how age, comorbidities, dose selection, and baseline patient risk influence treatment decisions with oral JAK inhibitors.\n4.\tExplain the role of shared decision-making and risk-benefit communication when treating adolescents, adults, and older patients with AD.\n5.\tRecognize practical considerations around zoster vaccination and routine immunization when initiating JAK inhibitor therapy.\n\n🎧 Tune in for a practical, nuanced, and slightly puppy-interrupted breakdown of what this data actually means for your clinic.\n#SkinAndJointsPodcast #AAD2026 #AtopicDermatitis #Dermatology #JAKInhibitors #Upadacitinib #Rinvoq #EczemaCare #DermTwitter #MedEd #HCPeducation #DermatologyPodcast #Vodcast #ClinicalPearls #SharedDecisionMaking #SkinScience #ADTreatment\n\n\nREFERENCES: \n\nLong-Term 6-Year Safety of Upadacitinib in Moderate-to-Severe Atopic Dermatitis Across Ages: Results From Three Phase 3 Studies\n\n\n\nSupported by an IME Grant from ABBVIE."}